Salvatore Leotta, Uros Markovic, Andrea Duminuco, Antonino Mulè, Ferdinando Porretto, Vincenzo Federico, Massimo Gentile, Domenico Pastore, Luca Lo Nigro, Carmine Selleri, Bianca Serio, Valeria Calafiore, Caterina Patti, Elisa Mauro, Calogero Vetro, Cinzia Maugeri, Marina Parisi, Paolo Fiumara, Laura Parrinello, Sara Marino, Grazia Scuderi, Bruno Garibaldi, Maurizio Musso, Nicola Di Renzo, Ernesto Vigna, Enrica Antonia Martino, Francesco Di Raimondo, Giuseppe Milone
Blinatumomab is a bispecific T-cell engager approved for relapsed/refractory and minimal residual disease positive B-cell Acute Lymphoblastic Leukemia. We conducted a retrospective study evaluating the outcome of Blinatumomab. The impact of clinical and treatment-related variables on cumulative incidence of relapse/progression (CIRP), event-free (EFS) and overall survival (OS) was analyzed. From January 2016 to December 2022 50 Ph'- (37) and Ph+ (13) B-ALL patients received Blinatumomab. The median age was 37...
April 13, 2024: Annals of Hematology